Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R744 (Mircera) vs Epoetin Beta in Hemodialysis Patients
NCT00491868Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jun 2007
- Primary completion
- May 2008
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Epoetin alfa RB in anemia of chronic kidney disease (4 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Variation of Hb concentration from baseline. Started Jun 2007; status: completed.
02
Drugs
Epoetin alfa RB
03
Conditions
anemia of chronic kidney disease
Beyond the preview
Go deeper on NCT00491868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00491868.